The high -dose efluelda (Sanofi) antigripping vaccine and the Fluad adjuvant (CSL Seqirus) vaccine preferentially recommended for people 65 and over, have just obtained their reimbursement. Pharmacists can now order for the next vaccination campaign. However, the price of the Efluelda vaccine was revised downwards… practical details.
Everything is (finally) gathered so that the highly dosed trivalent antigript vaccine EFLUELDA joins the flu vaccination campaign next fall. He has just been registered on the list of drugs refundable by health insurance, according to an order published in the “Official Journal” of July 24. We also know its price: 23.97 euros (against 30.90 euros before the suspension of placing its tetravalent form in 2024).
Efluelda, four times more dosed in antigens than a standard vaccine, is reimbursed only in adults aged 65 and over, 100 %, on health insurance. Like Fluad, awarded vaccine (MF59C.1, making it possible to increase and extend the duration of the immune response), which makes its entry according to the same conditions of care and at the same price as Efluelda (23.97 euros).
Both must be favored for antigrippal vaccines at standard doses in people 65 and over. In practice, Efluelda and Fluad are presented in pre -filled syringe.
Order terms
The doses of vaccines will be ready for the 2025-2026 campaign, the two laboratories announced. Pharmacists can already order.
For Efluelda, “Pharmacists who wish to offer this vaccine from the Gippale season 2025-2026 must now contact their wholesale distributors”, recommends Sanofi, questioned by “the daily life of the pharmacist”. For pharmacists who have already ordered the standard Vaxigrip vaccine, it is possible to switch part of the volumes pre -ordered on EFLUELDA. The approach is to be carried out with Sanofi.
As for Fluad, “Pharmacists can place an order via the customer service number: 01 72 95 00 72 Monday to Friday from 8:30 am to 5:30 pm”specifies CSL Seqirus to “daily”.
Efluelda: A story with twists and turns
Efluelda therefore returns to the market in a trivalent form as recommended by the WHO, after being out of the last vaccination campaign 2024-2025 for lack of agreement on its price. The health authorities also considered that this highly dosed vaccine had not demonstrated its superiority over the standard vaccines.
After a particularly severe influenza epidemic in 2024-2025, the High Authority for Health (HAS), however, changed their minds on the position of this improved vaccine in the vaccine strategy. In May, she preferentially recommended Efluelda or the Fluad vaccine in people aged 65 and over, compared to standard vaccines. HAS estimates that these two vaccines reduce hospitalizations each year (between 750 and 8,410) and consultations (between 4,500 and 24,290) linked to flu in 65 and over, compared to standard vaccines.
An opinion that has changed everything for Sanofi, who therefore left for negotiations with the authorities on the price of his vaccine. A price he refuses to comment.